Apoptosis in human autoimmune diseases

International Reviews of Immunology

Volumn 18, Issue 5-6, 1999, Pages 563-589

  Ravirajan, Chelliah T ^a   Pittoni, Valerio ^a   Isenberg, David A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Apoptosis; Autoimmune diseases; Autoimmunity

Indexed keywords

EID: 0033401463     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.3109/08830189909088499     Document Type: Review

References (119)

1. A.J. Levine. The tumor suppressor genes. Ann. Rev. Biochem, 62, 623-51, 1993.
2. J.F.R Kerr, A.H. Wyllie and A.R. Currie. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J. Cancer. 26, 239-57, 1972.
3. J. Savill. Apoptosis: from worm to wonder-drug? Br. J. Rheum. 34, 95-100, 1995.
4. J. Savill, K. Fado, P. Henson and C. Haslett. Phagocyte recognition of cells undergoing apoptosis. Immunol. Today 14, 131-36, 1993
5. A.K. Vaishnaw, J.D. McNally and K.B. Elkon. Apoptosis in the rheumatic diseases. Arthritis Rheum. 40, 1917-27, 1997.
6. D.A. Carson and J.M. Ribeiro. Apoptosis and disease. Lancet 341, 1251-54, 1993.
7. C. Roy, D.L. Brown, J.E. Little, B.K. Valentine, P.R. Walker, M. Sikorska, J. Leblanc and N. Chaly. The topoisomerase II inhibitor teniposide (VM-26) induces apoptosis in unstimulated mature murine lymphocytes. Exp. Cell Res. 200, 416-423, 1992.
8. Y A Ioannou and F.W. Chen. Quantitation of DNA fragmentation in apoptosis. Nucleic Acids Research 24, 992-93, 1996.
9. Z. Darzynkiewicz, S. Bruno, G. Del Bino, W. Gorczyca, M.A. Hotz, P. Lassota and F. Traganos. Features of apoptotic cells measured by flow cytometry. Cytometry 13, 795-808, 1992.
10. G. Koopman, C.P.M. Reutlingsperger, G.A.M. Kuijten, R.M.J Keehnen, S.T. Pals and M.H.J. van Oers. Annexin V for flow cytometry detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84, 1415-20, 1994.
11. C.E. Perandones, V.A. Illera, D. Peckham, L.L. Stunz and R.F. Ashman. Regulation of apoptosis in vitro in murine spleen T cells. J. Immunol. 151, 3521-3529, 1993.
12. P. Salgame, A.S. Varadhachary, L.L. Primiano, J.E. Fincke, S. Muller and M. Monestier. An ELISA for detection of apoptosis. Nucleic Acids Research 25, 680-681, 1997.
13. R. Gold, M. Schmid, G. Giegerich, H. Breitschope, H.P. Hartung, K.V. Toyka and H. Lassman. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation technique. Lab. Invest. 71, 219-25, 1994.
14. M.G. Tomlinson, A.F. Williams and M.D. Wright Epitope mapping of anti-rat CD53 monoclonal antibodies Implications for the membrane orientation of the Transmembrane 4 Superfamily. Eur. J. Immunol. 23, 136-40, 1993.
15. J.C. Reed. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124, 1-6, 1994.
16. Z.N. Oltvali, C.L. Milliman and S.J. Korsmeyer. Bcl-2 heterodimerises in vivo with a conserved homolog BAX, that accelerates programmed cell death. Cell 74, 609-19, 1993.
17. X.-M. Yin, Z.N. Oltvai and S.J. Korsmeyer. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerisation with BAX. Nature 369, 321-3, 1994.
18. L.H. Boise, C.E. Gonzalez-Garcia, C.E. Postema, L. Ding, T. Lindsten, L.A. Turka, G. Mao Nunez and C.B. Thompson. Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608, 1993.
19. K.M. Kozopas, T. Yang, H.L. Buchan, P. Zhou and R.W. Craig. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to bcl-2. Proc. Natl. Acad. Sci. USA 90, 3516-3520, 1993.
20. B. Amati, T.D. Littlewood, G.I. Evan and H. Land. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J. 12, 5083-5087, 1993.
21. L. Kretzner, E.M. Blackwood and R.N. Eisenman. Myc and Max proteins possess distinct transcriptional activities. Nature 359, 426-429, 1992.
22. G I. Evan, A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H. Land, M. Brooks, C.M. Waters, L.Z. Penn and D-C. Hancock. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119-128, 1992.
23. Y Shi, J.M. Glunn, L.J. Guilbert, T.G. Cotter, R.P. Bissonnette and D.R. Green. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257, 212-214, 1992.
24. N. Itoh, S. Yonehara, A. Ishii, M. Yonehara, S.I. Mizushima, M. Sameshima, A. Hase, Y. Seto and S. Nagata. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243, 1991.
25. M. Adachi, R. Watanabe-Funaga and S. Nagata. Aberrant transcription caused by the insertion of an early transportable element in an intron of the Fas antigen gene of lpr mice. Proc Natl. Acad. Sci. USA 90, 1756-1760, 1993.
26. J D. Mountz and N. Talal. Retroviruses, apoptosis and ongogenes. Immunol. Today 14, 532-536, 1993.
27. T. Suda, T. Takahashi, P. Golstein and S. Nagata. Molecular cloning and expression of the fas ligand, a novel member of the tumour necrosis factor family.Cell 75, 1169-1178, 1993.
28. C. Klas, K.M. Debatin, R.R. Jonker and P.H. Krammer. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5, 625-630, 1993.
29. E. Mysler, P Bini, J. Drappa, P. Ramos, S. Friendman, P.H. Karammer and K.B. Elkon The apoptotis-1/fas protein in human systemic lupus erythematosus. J. Clin. Invest. 93, 1029-1034, 1994.
30. J. Marx. How p53 suppress cell growth. Science 262, 1644-1645, 1993.
31. O. Eisenberg, A. Faber-Elman, E. Gottlieb, M. Oren, V. Rotter and M. Schwartz. Direct involvement of p53 in programmed cell death of oligodendrocytes. EMBO J. 14, 1136-44, 1995.
32. Y. Noguchi, Y.T. Chen and L J. Old. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl. Acad. Sci. USA 91, 3171-3175, 1994.
33. L. Tuosto, E. Chundari, M.S.G. Montani and E. Piccolella. Analysis of susceptibility of mature human T lymphocytes to dexamethasone-induced apoptosis. Eur. J. Immunol. 24, 1061-1065, 1994.
34. A.M. Zubiaga, M. Eduardo and B.T. Huber. IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid-induced apoptosis. J. Immunol. 149, 107-112, 1992.
35. A.N. Akbar, N.J Borthwick, R.G. Wickremasinghe, P. Panayoitidis, D. Pilling, M. Bofill, S. Krajewski, J.C. Reed and M. Saimal. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to the growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol. 26, 294-299, 1996.
36. K.B. Elkon and A. Marshak-Rothstein. B cells in systemic autoimmune disease: recent insights from Fas-dependent mice and men. Curr. Opin. Immunol. 8, 852-859, 1996.
37. A.H. Wyllie. Apoptosis: an overview. British Medical Bulletin 53, 451-465, 1997.
38. F. Oberhammer, M. Pavelka, S. Sushitra, R. Tiefenbacher, A.F. Purchio, W. Bursch and W. Schult-Herman. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc. Natl. Acad. Sci. USA 89, 5408-5412, 1992.
39. R. Alam, P. Frorsytbe, S. Stafford and Y. Fukuda Transforming growth factor β abrogate the effects of haematopoietins on eosinophils and induces their apoptosis. J. Exp. Med. 179, 1041-1045, 1994.
40. M. Lotz, E. Ranheim and T.J. Kipps. Transforming growth factor β as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J. Exp. Med. 179, 999-1004, 1994.
41. J. Lotem and K. Saches. Haematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80, 1750-1757, 1992.
42. F. Novelli, F. Di Pierro, P. Di Celle, S. Bertini, P. Affaticati, G. Garotta and G. Forni. Environmental signals influencing expression of the INF-γ receptor on human T cells control whether INF-γ promotes production or apoptosis. J. Immunol. 152, 496-504, 1994.
43. F. Rousset, E. Garcia, T. De France, C. Peronne, N. Vezzio, D.H. Hsu, K.W. Moore and J. Banchereau. Interleukin-10 is a potent growth and differentiation factor for cell death of B-chronic lymphocytic leukemia cells. J. Exp. Med. 179, 91-99, 1992.
44. A.C. Fluckiger, I. Durand and J. Banchereau. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukaemia cells. J. Exp. Med. 179, 91-99, 1995.
45. Y. Levy and J.C. Brouet. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J. Clin. Invest. 93, 424-428, 1994.
46. K. Taga, B. Cherney, and G Tosato. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int. Immunol. 5, 1599-1608, 1993.
47. J. Cambier and J.T. Ransom. Molecular mechanisms of transmembrane signalling in B lymphocytes. Ann. Rev. Immunol. 5, 175-199, 1987.
48. S.L. Parry, J. Hasbold, M. Holman and G.B. Klaus. Hypercross-linking surface IgM or IgD receptors on mature B cells induces apoptosis that is reversed by costimulation with IL-4 and anti-CD40. J. Immunol. 152, 2821-2829, 1994.
49. M K. Newell, J. Vanderwall, K.S. Beard and J.H. Freed. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc. Natl. Acad. Sci. USA 90, 10459-10463, 1993.
50. C.D. Surh and J. Sprent. T-cell apoptosis detected in situ during positive and negative selection in the thymus (see comments). Nature 372, 100-3, 1994.
51. P. Mombaerts, J. Iacomini, R.S. Johnson, K. Herrup, S. Tonegawa and V.E. Papaioannou. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869-77, 1992.
52. Y. Shinkai, G. Rathburn, K.P. Lam, E.M. Oity, V. Stewart, M. Mendelson, J. Charron and M. Datta, F. Young and A.M. Stall. RAG-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855-67, 1992.
53. J.A. Punt, B.A. Osborne, Y. Takahama, S.O. Sharrow and A. Singer. Negative selection of CD4+CD8+ thymocytes by T cell receptor-induced apoptosis requires a costimulatory signal that can be provided by CD28. J Exp. Med. 179, 709-713, 1994.
54. R H. Schwartz Models of T cell anergy. is there a common molecular mechanism? J. Exp. Med. 184, 1-8, 1996.
55. E. Sebzda, V.A. Wallace, J. Mayer, S.M. Young, T.W. Mak and P.S. Ohashi. Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science 263, 1615-1618, 1994.
56. S. Nagata and P. Golstein. The fas death factor. Science 267, 1449-1456, 1995.
57. G.J.V. Nossal. Clonal anergy of B cells: a flexible, reversible, and quantitative concept. J Exp. Med 183, 1953-1956; 1996.
58. S.M. Lens, K. Tesselaar, B.F. den Drijver, M.H. van Oers and R.A. van Lier. A dual role for both CD40-ligand and TNF-α in controlling human B cell death. J. Immunol. 156, 507-14, 1996.
59. C.C. Goodnow. Transgenic mice and analysis of B cell tolerance. Annu. Rev. Immunol. 10, 489-518, 1992.
60. J.C. Rathmell, S.E. Townsend, J.C. Xu, R.A. Flavell and C.C. Goodnow. Expansion or elimination of B cells in vivo: dual roles for CD40 and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 57, 319-329, 1996.
61. G. Koopman, R.M.J. Keehnen, E. Lindhout, W. Newman, Y. Shimizu, G.A. Van Seventer, C. De Groot and S.T. Pals. Adhesion through the LFA-1 (CD11α CD18)-ICAM-1 (CD54) and the VLA-4 (CD49α)-VCAM-1 (CD106) pathways prevents apoptosis of germinal centre B Cells. J. Immnnol. 152, 3760-3767, 1994.
62. E. Flescher and N. Talal. Do viruses contribute to the development of Sjögren's syndrome? Am. J. Med. 90, 283-285, 1991.
63. S. Henderson, M. Rowe, C. Gregory, D. Croom-Carter, F. Wang, R. Longnecker, E. Kieff and A. Rickinson. Induction of bcl-2 expression by Epstein-Bar virus latent membrane protein protects infected B cells from programmed cell death. Cell 65, 1107-1115, 1991.
64. R. Watanabe-Fukunaga, C.I. Brannan, N.G. Copeland, N.A. Jenkis and S. Nagata. Lymphoproliferation disorder in mice explained by defect in Fas antigen that mediates apoptosis. Nature 356, 314-17, 1992.
65. S. Nagata and T. Suda. Fas and Fas ligand. lpr and gld mutations. Immunol. Today 16, 39-43, 1995.
66. C.T. Ravirajan, C.E. Sarraf, T.V. Amlkumar, M.C.H. Golding, M.R. Alison and D.A. Isenberg. An analysis of apoptosis in lymphoid organs and lupus disease in murine systemic erithematosus (SLE). Clin. Exp Immunol. 105, 306-12, 1996.
67. J. Cheng, T. Zhou, C. Liu, J.P Shapiro, M.J. Brauer, M.C. Kiefer, P.J. Barr and J.P. Mountz. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263, 1759-62, 1994.
68. V.C. Canale and C.H. Smith. Chronic lymphadenopathy simulating malignant lymphoma J. Pediatr. 70, 891-9, 1967.
69. F Le Derst, J.F. Emile, F. Rieux-Laucat, M. Benkerrou, I. Roberts, N. Brousse and A. Fischer Clinical immunological and pathological consequences of Fas-deficient conditions. Lancet 348, 719-23, 1996.
70. F. Rieux-Lacat, F. Le Derst, C. Hivroz, I A.G. Roberts, K.M. Debatin, A. Fisher and J.P. de Villartay. Mutation in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347-49, 1995
71. G.H. Fisher, F.J. Rosenberg, S.E. Straus, J K. Dale, L.A. Middelton, A.Y. Lin, W. Strober, M.J. Lenardo and J.M. Puck. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935-46, 1995.
72. W. Emlen, J. Niebur and R. Kadera. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus J. Immunol. 152, 3685-92, 1994.
73. H. Martin Lorenz, M. Grunke, T. Hieronymus, M. Herrmann, A. Kuhnel, B. Manger and J.R. Kalden. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and autoimmune diseases. Arthritis and Rheum. 40, 306-17, 1997.
74. J. Wu, J. Wilson, J. He, L. Xiang, P.H. Schur and J.D. Mountz. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J. Clin. Invest. 98, 1107-13, 1998.
75. L.M Rose, D.S. Latchman and D.A. Isenberg. Elevate soluble Fas production in SLE correlates with HLA status not with disease. Lupus 6, 717, 1997.
76. A. Strasser, S. Whittingham, D.L. Vaux, M.L. Bath, J.M. Adams, S. Cory and A.W. Harris. Enforced Bcl-2 expression in B lymphoid cells prolongs antibody response and elicits autoimmune disease. Proc. Natl. Acad. Sci. USA 88, 8661-65, 1991.
77. T.J. Mc Donnell, N. Deane, F.M. Platt, G. Nunez, U. Jaeger, J.P. Mc Kearn and S.J. Korsmeyer BCl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57, 79-88, 1989.
78. T.J. Mc Donnell, G. Nunez, F.M. Platt, D. Hockenbery, L London, J.P. Mc Kearn and S.J Korsmeyer. Deregulated bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol. Cell. Biol. 10, 1901-7, 1990
79. M. Aringer, W. Wintersberger, C.W. Steiner, H. Kiener, E. Presterl, U. Jaeger, J.S Smolen and W.B. Graninger. High levels of Bcl-2 protein in circulating T lymphocytes, but not B lympocytes of patients with systemic lupus erythematosus. Arthritis Rheum. 37. 1423-30, 1994.
80. L. Casciola-Rosen, A. Rosen, M. Petri and M. Schlissel. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implication for coagulation events and antigenic spread in systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 93, 1624-29, 1996.
81. C.T. Ravirajan, I. Harmer, T. McNally, A. Hohmann, C.G. Mackworth-Young and D.A. Isenberg. Phospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 54, 471-76, 1995
82. F. Topfer, T. Gordon and J. McCluskey. Intra- and Intermolecular spreading of autoimmunity involving the nuclear self-antigens LA(SSB) and Ro (SSA). Proc. Natl. Acad. Sci. USA 92, 875-79,1995.
83. L.A. Caciola-Rosen, D.K. Miller, G.J. Anhalt and A. Rosen. Specific cleavage of the 70 kD protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J. Biol. Chem. 269, 30757-60, 1994.
84. D.J. Jacobson. Reactive oxygen species and programmed cell death. T.I.B.S. 21, 83, 1996.
85. A.R Cross and O.T.G. Jones Enzymatic mechanism of superoxide production. Biochim. Biophys Acta. 1057, 281-98, 1991
86. A. Rosen, R.L. Casciola and J. Ahearn. Novel packages of viral and self-antigens are generated during apoptosis J. Exp. Med. 181, 1557-61, 1995.
87. L.C. Korb and J.M. Ahearn. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes. J. Immunol. 158, 4525-28, 1997.
88. A. Kawakami, K. Eugushi, N. Matsuoka, M. Tsuboi, Y. Kawabe, T. Aoyagi and S. Nagataki. Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial cells in vitro by transforming growth factor β1. Arthritis Rheum. 39, 1267-76, 1996
89. M. Tsuboi, K. Eugushi, A. Kawakami, N. Matsuoka, Y. Kawabe, T. Aoyagi, K. Maeda and S. Nagataki. Fas antigen expressiom on synovial cells was downregulated by interleukin 1. Biochem. Biophys. Res. Com. 218, 280-85, 1996.
90. M. Sugiyama, T. Tsukazaki, A. Yonekura, S. Matsuzaki, S. Yamashita and K. Iwasaki. Localization of apoptosis and expression of apoptosis-related molecules in the synovium of patients with rheumatoid arthritis. Ann. Rheum. Dis. 55, 442-49, 1996.
91. G.S. Firestein, K. Nguyen, K.R. Aupperle, M. Yeo and N.J. Zvaifler. Apoptosis in rheumatoid arthritis. II. p53 overexpression in rheumatoid arthritis synovium. Am. J. Pathol. 149, 2143-51, 1996.
92. G.S. Firestein, M. Yeo and N.J. Zvaifler. Apoptosis in rheumatoid arthritis synovium. J. Clin. Invest. 1631-38, 1995.
93. T. Nakajima, H. Aono, T. Hasunuma, K. Yamamoto, T. Shirai, K. Hirohata and K. Nishioka. Apoptosis and functional Fas antigen in rheumatoid arhtritis synoviocytes. Arthritis Rheum. 38, 485-91, 1995.
94. M.J. Cantwell, T. Hua, N.J. Zvaifler and T.J. Kipps. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis and Rheum. 40, 1644-52, 1997.
95. M. Salmon, D. Scheel-Toellner, A.P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A. Dupuy d'Angeac, P.A. Bacon, P. Emery and A.N. Akbar. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99, 439-46, 1997.
96. T. Hasunuma, N. Kayagashi, H. Asahara, S. Motokawa, T. Kobata, H. Yagita, H. Aono, T. Sumida, K. Okomura, and K. Nishioka. Accumulation of soluble Fas in inflammed joints of patients with rheumatoid arthritis. Arthritis and Rheum. 40, 80-86, 1997.
97. A.L. Bell, M.K. Magill, R. Mc Kane and A.E. Irvine. Human blood and synovial fluid neutrophils cultered in vitro undergo programmed cell death which is promoted by the addition of synovial fluid. Ann. Rheum. Dis. 54, 910-15, 1995.
98. L. Kong, N. Ogawa, T. Nakabayashi, G.T. Liu, E. D'Souza, H.S. McGuff, D. Guerrero, N. Talal and H. Dang. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögrer's syndrome. Arthritis and Rheum 40, 87-97, 1997
99. R. Matsumura, M. Kagami, H. Tomioka, E. Tanabe, T Sugiyama, M. Sueishi, A. Nakajima, M. Azuma and K. Okumura. Expression of ductal Fas antigen in sialoadenitis of Sjögren's syndrome. Clin Exp. Rheumatol 14, 309-11, 1996.
100. L. Kong, N. Ogawa, R. Masago, N. Talal and H. Dang. Bcl-2 family in salivary gland from Sjögren syndrome: Bax may be involved in the distruction of SS salivary glandular epithelium. Arthritis and Rheum. 39 (suppl. 9). S289, 1996.
101. T. Sumida, I Matsumoto, H Murata, T. Namekawa, R. Matsumura, H. Tomioka, I. Iwamoto, Y. Saito, Y. Mizushima, T. Hasunuma, T. Maeda and K. Nishioka. TCR in Fas-sensitive T cells from labial salivary glands of patients with Sjogren's syndrome J Immunol. 158, 1020-25, 1997.
102. R Snonc, M.S Gruschwitz, H Dietrich, H. Recheis, M E. Gershwin and G. Wick. Endothelial cell apoptosis is a primary pathogenic event underlyining skin lesions in avian and human scleroderma. J. Clin. Invest. 98, 785-92, 1996.
103. R. Simantov, J M. La Sala, S.K. Lo, A.E. Gharavi, L.R. Sammaritano, J.E. Salmon and R L. Silverstein. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J. Clin. Invest. 96, 2211-19, 1995
104. W L Gross, W.H. Schmitt and E. Csernok. ANCA and associated diseases: immunodiagnostic and pathogenic aspects. AU: Clin. Exp. Immunol 91, 1-12, 1993.
105. G. D'Amico, R.A. Sinico and F. Ferrano. Renal vasculitis. Nephrol. Dial. Transplant. 11, 69-74, 1996.
106. H.M Gilligan, B. Bredy, H.R. Brady, M.J. Hebert, H.S. Slayter, Y. Xu, J. Rauch, M.A. Shia, J.S. Koh and J.S. Levine. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J. Exp. Med. 184, 2231-41, 1996.
107. L.J. Hammond, M.W. Lowdell, P.G. Cerrano, A.W. Goode, G.F. Bottazzo and R. Mirakian. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. J. Pathol. 182, 138-44, 1997.
108. S. Dremier, J. Goistein, R. Mosselmans, J.E. Dumont, P. Galand and B. Robaye. Apoptosis in dog thyroid cells. Biochem. Biophys. Res. Commun. 200, 52-58, 1994.
109. T.S. Griffith, T. Brunner, S.M. Fletcher, D.R. Green and T.A. Ferguson. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-92, 1995.
110. C. Giordano, G. Stassi, R. De Maria, M. Todaro, P. Richiusa, G. Papoff, G. Ruberti, M. Bagnasco, R. Testi and A. Galluzzo. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275, 960-63, 1997.
111. A.V. Chervonsky, Y. Wang, F.S Wong, I. Visintin, R.A. Flavell, C.A. Janeway, Jr and L.A. Matis. The role of Fas in autoimmune diabetes. Cell 89, 17-24, 1997.
112. M.O. Kurrer, V. Symasundar, S.V. Pakala, H.L. Hanson and J.D. Katz. B cell apoptosis in T cell-mediated autoimmune diabetes. Proc. Natl. Acad. Sci USA 94, 213-18, 1997.
113. C.S. Raine. The Norton lecture: a review of the oligodendorcytes of in the multiple sclerosis lesion. J. Neuroimmunol. 77, 135-52, 1997.
114. K.A. Sabelko, K.A. Kelly, M.H. Naham, A.H. Cross and J.H. Russell. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyclitis. but are not essential for immune privilege in the central nervous system. J. Immunol. 159, 3096-99, 1997
115. H. Waldner, RA. Sobel, E. Howard and V.K. Kuchro. Fas and FasL deficient mice are resistent to induction of autoimmune encephalomyclitis. J. Immunol. 159, 3100-3, 1997.
116. S.D. D'Souza, B. Bonetti, V. Balasingam, N.R Cashamn, P.A. Baker, A B. Troutt, C.S. Raine and J.P. Antel. Multiple sclerosis: Fas signalling in olygodendrocyte cell death J. Exp. Med. 184, 2361-70, 1996.
117. B. Bonetti and C.S. Raine. Multiple Sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. 42, 74-84, 1997.
118. C.F Lucchinetti, W. Bruck, M. Rodriguez and H. Lassmann. Distinct pattern of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol. 6, 259-74, 1996.
119. R. Gold, H.P. Hartung and H. Lassmann. T cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci. 20, 399-404, 1997.